ArticleAntimicrobial agents and chemotherapy2013
Risk factors for a low linezolid trough plasma concentration in acute infections.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2022Pooled it
- Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic review.Critical care (London, England) · 2016Pooled it
- Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.Clinical pharmacokinetics · 2017Trial
- A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations.Antibiotics (Basel, Switzerland) · 2023Review
- Are Antibiotics Appropriately Dosed in Critically Ill Patients with Augmented Renal Clearance? A Narrative Review.International journal of clinical practice · 2022Review
- Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity.Antimicrobial agents and chemotherapy · 2021Article
- Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.BMC pharmacology & toxicology · 2021Observational
- Disseminated septic arthritis caused byBMJ case reports · 2020Article
- Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study.Annals of translational medicine · 2020Article
- Determining therapeutic trough ranges for linezolid.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Article
- Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.Antimicrobial agents and chemotherapy · 2019Article
- Evaluation of treatment options for methicillin-resistantInfection and drug resistance · 2019Article
- Pharmacokinetics and pharmacodynamics of Linezolid in burn patients.Annals of burns and fire disasters · 2018Article
- Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.Clinical pharmacokinetics · 2018Review
- Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?Clinical pharmacokinetics · 2018Review
- Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.Antimicrobial agents and chemotherapy · 2017Article
- Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.Drug design, development and therapy · 2017Review
- Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.Antimicrobial agents and chemotherapy · 2016Observational
- Continuous administration of linezolid in pneumonia: what is the level of proof?Intensive care medicine · 2015Article
- Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid is an antibiotic with time-dependent activity, and both the percentage of time that plasma concentrations exceed the MIC and the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC24/MIC ratio) are associated with clinical response. The aim of this study was to analyze the linezolid trough plasma concentration (C(min)) and to determine factors associated with a C(min) < 2 mg/liter and other clinically relevant thresholds. Characteristics of 78 patients receiving 600 mg/12 h of linezolid with a C(min) determination at the steady state and within the first 10 days of treatment were retrospectively reviewed. Concentrations were measured using high-pressure liquid chromatography. Univariate and multivariate analysis were performed to identify risk factors of low C(min). A total of 29.5% of patients had a C(min) < 2 mg/liter. The percentage was significantly higher in patients with an estimated glomerular filtration (eGF) > 80 ml/min, in intensive care unit (ICU) patients, and in patients with an infection due to Staphylococcus aureus. The independent predictors of C(min) < 2 mg/liter were an eGF > 80 ml/min (odds ratio [OR], 10; 95% confidence interval [CI], 2.732 to 37.037; P = 0.001) and infection due to S. aureus (OR, 5.906; 95% CI, 1.651 to 21.126; P = 0.006). A linezolid C(min) of <2 mg/liter was found in 29.5% of cases, and the risk was significantly higher among those with an eGF > 80 ml/min and in infections due to S. aureus. In patients with severe sepsis, a loading dose or continuous infusion and drug monitoring could improve the pharmacodynamic parameters associated with linezolid efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.